Organisation paid for research Program year 2025 Source: CMS Open Payments

Columbia Dermatology

Neither a doctor nor a teaching hospital

Research payments

$434,658

29 payments

Through program year 2025, Columbia Dermatology is reported as receiving $434,658 in research payments, across 29 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $287,606 22
2024 Research $144,298 6
2023 Research $2,754 1

Breakdown

Who paid Research payments · program years 2023–2025
  1. Eli Lilly and Company $324,092 8 payments
  2. Sanofi US Services Inc. $103,159 17 payments
  3. Pfizer Inc. $7,408 4 payments
Studies the money was for Research payments · program years 2023–2025
  1. A Phase 2B, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa $291,102 2 payments
  2. A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis $50,164 8 payments
  3. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis $39,395 8 payments
  4. Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-To-Severe Plaque Psoriasis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Pso) $18,392 3 payments
  5. Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO) $13,600 1 payment
  6. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Moderate-To-Severe Plaque Psoriasis and Obesity Or Overweight in Clinical Practice $7,540 1 payment
  7. A Phase 3 Randomized Doubleblind 52Week Placebocontrolled Multicenter Study With A Doubleblind 52Week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo $7,408 4 payments
  8. Psosa (Psoriasis Special Areas) - A US-Based, Single-Arm, Prospective, Multicenter, Observational Study of Nail and Scalp Psoriasis Improvement in Patients Treated With Ixekizumab $4,304 1 payment
  9. Psosa (Psoriasis Special Areas) - A US-Based Single-Arm Prospective Multicenter Observational Study of Nail and Scalp Psoriasis Improvement in Patients Treated With Ixekizumab $2,754 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record